Abstract YO23
Case summary
Soft tissue Giant cell tumor presented as Nasopharyngeal mass : A case Report
ABSTRACT:
Background:
Primary soft tissue giant cell tumors are exceedingly rare. These often present in the elderly and are mostly noted on the extremities. Morphologically, these tumors resemble their osseous counterparts but sequencing studies have suggested that these two may be genetically distinct. Surgical extirpation remains standard of treatment; but for those with unresectable disease treatment options are less clear. For these patients, the use of bisphosphonates and RANK-L directed biologic therapy have been reported in the literature.
Case presentation:
A 30 year old male consulted at our medical oncology clinic with the chief complaint of diplopia. Magnetic resonance imaging (MRI) of the head revealed an enhancing soft tissue mass at the nasopharyngeal wall measuring 5.8x5.5x5.1cm extending anteriorly at the posterior margin of the nasal cavity, both parasellar regions, leptomeningeal region of the medial aspect of both middle cranial fossa, and infiltrating into the clivus. No distant metastasis was seen. Punch biopsy of this nasopharyngeal mass favored a giant cell tumor. Immunohistochemical staining was done with the following results: Cytokeratin negative, CD68 positive, and Vimentin positive, all consistent with giant cell tumor. Due to its location, the tumor was regarded to be unresectable. Zoledronic acid was given once every 28 days for 3 months. Cranial CT scan done after three months of treatment revealed an enhancing nasopharyngeal mass measuring 6.0x5.0x4.0cm with intracranial extension. At this time despite demonstrating stable disease, the patient was noted to have worsening of symptoms and was then shifted to Denosumab.
Conclusion:
We have reported a case of a nasopharyngeal giant cell tumor, which is an uncommon presentation of a rare soft tissue tumor. While surgery is the preferred treatment for this disease, the location of this tumor precluded resection. This has prompted the decision to employ systemic treatment with Zoledronic acid and subsequently Denosumab for this patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
303P - Segmental mandibulectomy without reconstruction
Presenter: Yohei Morishita
Session: Poster display session
Resources:
Abstract
304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
Presenter: Filipa Pontes
Session: Poster display session
Resources:
Abstract
305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
Presenter: Tetsuro Wakasugi
Session: Poster display session
Resources:
Abstract
306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
Presenter: Lin Gui
Session: Poster display session
Resources:
Abstract
307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
Presenter: Mahmoud KhalafAllah
Session: Poster display session
Resources:
Abstract
308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Presenter: Yi-Fang Huang
Session: Poster display session
Resources:
Abstract
309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Presenter: Ai Horinouchi
Session: Poster display session
Resources:
Abstract
310P - Laser and PDT for the oral leukoplakia
Presenter: Sadykov Rasul
Session: Poster display session
Resources:
Abstract
311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
Presenter: Priscilla Caguioa
Session: Poster display session
Resources:
Abstract
312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
Presenter: Shanavas Palliyal
Session: Poster display session
Resources:
Abstract